1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Nonalcoholic steatohepatitis (NASH) - Pipeline Insight, 2021

Nonalcoholic steatohepatitis (NASH) - Pipeline Insight, 2021

  • March 2021
  • 240 pages
  • ID: 6036531
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

“Nonalcoholic steatohepatitis (NASH) – Pipeline Insight, 2021,” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Nonalcoholic steatohepatitis (NASH) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Nonalcoholic steatohepatitis (NASH) Understanding

Nonalcoholic steatohepatitis (NASH): Overview
Non-Alcoholic Steatohepatitis, liver inflammation and damage caused by a buildup of fat in the liver. Nonalcoholic fatty liver disease (NAFLD) is an umbrella term for a range of liver conditions. The more severe form of NAFLD is called nonalcoholic steatohepatitis (NASH). NASH causes the liver to swell and become damaged. When the buildup of fat causes inflammation and damage this can lead to the scarring of the liver. The main complication of NAFLD and NASH is cirrhosis, which is late-stage scarring in the liver. Cirrhosis occurs in response to liver injury, such as the inflammation in NASH. There is no standard treatment for patients NASH, lifestyle changes have been shown to affect its progression. This may include losing weight, maintaining a healthy diet, or addressing underlying conditions such as hypothyroidism and diabetes.

"Nonalcoholic steatohepatitis (NASH) - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nonalcoholic steatohepatitis (NASH) pipeline landscape is provided which includes the disease overview and Nonalcoholic steatohepatitis (NASH) treatment guidelines. The assessment part of the report embraces, in depth Nonalcoholic steatohepatitis (NASH) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nonalcoholic steatohepatitis (NASH) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Nonalcoholic steatohepatitis (NASH) R&D. The therapies under development are focused on novel approaches to treat/improve Nonalcoholic steatohepatitis (NASH).

Nonalcoholic steatohepatitis (NASH) Emerging Drugs Chapters
This segment of the Nonalcoholic steatohepatitis (NASH) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nonalcoholic steatohepatitis (NASH) Emerging Drugs
- Oltipraz: Pharmaking
Oltipraz is a synthetic dithiolethione with potential chemopreventive and anti-angiogenic properties. Oltipraz induces phase II detoxification enzymes, such as glutathione S transferase (GST) and NAD(P)H:quinone oxidoreductase 1 (NQO1). The induction of detoxification enzymes enhances the detoxification of certain cancer-causing agents, thereby enhancing their elimination and preventing carcinogen-induced DNA damages. The drug is in phase III clinical trials for the treatment of NASH.

- MGL-3196: Madrigal Pharmaceuticals
Resmetirom (MGL-3196) is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ?-selective agonist. THR-? selectivity enhances the safety profile of resmetirom, compared to non-selective agents. Resmetirom neither suppresses the central thyroid axis nor THR-? effects on heart rate or bone, and it reduces elevated liver enzymes in NASH patients. Madrigal Pharmaceuticals plans to submit marketing approval application in Non-alcoholic steatohepatitis to the US FDA.

- Aramchol: Galmed Pharmaceuticals
Aramcho (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate. Aramcho is a first in class, orally active, liver targeted SCD – 1 modulator with a dual mode of action on liver fibrosis, down regulation of steatosis and a direct effect on Hepatic Stellate Cells (HSC’s), the human collagen producing cells. The drug is currently being studied in phase III stage of development for NASH.

- TERN-101: Terns Pharmaceuticals
TERN-101 is currently being evaluated in phase II clinical trial in patients diagnosed with NASH. TERN-101 is a liver-distributed, non-bile acid FXR agonist. FXR is a nuclear receptor primarily expressed in the liver, intestine and kidneys. FXR regulates hepatic expression of various genes involved in lipid metabolism, inflammation and fibrosis.

- EYP001: ENYO Pharma
EYP001 which is an orally bioavailable synthetic non-steroidal, non-bile acid FXR agonist small molecule developed for the treatment of patients with NASH. The drug is being studied in phase II stage of development.
- EDP 297: Enanta Pharmaceuticals
EDP-297 represents a class of FXR agonists that has been designed to take advantage of increased binding interactions with the receptor. EDP-297 demonstrate potent anti-fibrotic, anti-inflammatory and hepatoprotective effects. Currently the drug is being evaluated in phase I clinical trials for NASH.
Further product details are provided in the report……..

Nonalcoholic steatohepatitis (NASH): Therapeutic Assessment
This segment of the report provides insights about the different Nonalcoholic steatohepatitis (NASH) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Nonalcoholic steatohepatitis (NASH)
There are approx. 5+ key companies which are developing the therapies for Nonalcoholic steatohepatitis (NASH). The companies which have their Nonalcoholic steatohepatitis (NASH) drug candidates in the most advanced stage, i.e. phase III include, Orbus Therapeutics, Inc.
- Phases
This report covers around 5+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

- Route of Administration
Nonalcoholic steatohepatitis (NASH) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Subcutaneous
• Intravenous
• Intramuscular

- Molecule Type
Products have been categorized under various Molecule types such as
• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nonalcoholic steatohepatitis (NASH): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nonalcoholic steatohepatitis (NASH) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nonalcoholic steatohepatitis (NASH) drugs.

Nonalcoholic steatohepatitis (NASH) Report Insights
• Nonalcoholic steatohepatitis (NASH) Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Nonalcoholic steatohepatitis (NASH) Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Nonalcoholic steatohepatitis (NASH) drugs?
• How many Nonalcoholic steatohepatitis (NASH) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nonalcoholic steatohepatitis (NASH)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nonalcoholic steatohepatitis (NASH) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Nonalcoholic steatohepatitis (NASH) and their status?
• What are the key designations that have been granted to the emerging drugs?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Anal Fistula Treatment Industry

  • $ 4950
  • April 2021
  • 104 pages

Abstract: - Global Anal Fistula Treatment Market to Reach $760.7 Million by 2027 - Amid the COVID-19 crisis, the global market for Anal Fistula Treatment estimated at US$579.2 Million in the year 2020, ...

  • World
  • China
  • Digestive System Disorder
  • Industry analysis

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on